Vascular Biology |
From Bristol Heart Institute (T.W.J., Y.X.W., A.B., A.C.N., K.R.K., M.O.), University of Bristol, Bristol, UK; and the Department of Cardiology (C.H.), University of Tübingen, Tübingen, Germany.
Correspondence to Professor Karl R. Karsch, Bristol Heart Institute, University of Bristol, Bristol, UK, BS2 8HW. E-mail K.R.Karsch{at}bristol.ac.uk
Background Stent-based antiproliferative therapy appears to decrease in-stent restenosis. However, alternative approaches might produce equivalent efficacy with better long-term safety. In previous work, an adenovirus capable of expressing the tissue inhibitor of metalloproteinase-3 (RAdTIMP-3) inhibited neointima formation in cell cultures and porcine saphenous vein grafts. RAdTIMP-3 decreased smooth muscle cell migration, stabilized the extracellular matrix, and uniquely promoted apoptosis. The current study developed eluting stent technology to deliver RAdTIMP-3 during stenting of pig coronary arteries.
Methods and Results Binding of virus to and elution from stents and transduction of pig coronary arteries were confirmed using ß-galactosidase as a reporter gene in vitro and in vivo. Deployment of RAdTIMP-3coated stents increased apoptosis and reduced neointimal cell density, but did not increase inflammation or proliferation compared with ß-galactosidaseexpressing adenovirus (RAdlacZ). Neointimal area after 28 days was significantly reduced to 1.27±0.19 mm2 with RAdTIMP-3 versus 2.61±0.31 mm2 with RAdlacZ stents (P<0.001) and 2.12±0.20 mm2 with bare stents (P<0.005).
Conclusions Our results demonstrate for the first time to our knowledge the feasibility of adenovirus-coated stent technology and highlight the potential of TIMP-3 to produce significant inhibition of in-stent neointima formation.
We developed eluting-stent technology to deliver an adenovirus capable of TIMP-3 overexpression and investigated its effect on restenosis. The technology resulted in effective in vitro and in vivo transduction. TIMP-3 overexpression increased apoptosis and reduced neointimal formation. Our results demonstrate for the first time to our knowledge the feasibility of adenovirus-eluting stent technology.
Key Words: gene therapy metalloproteinases restenosis stents viruses
This article has been cited by other articles:
![]() |
Y. Takemoto, H. Kawata, T. Soeda, K. Imagawa, S. Somekawa, Y. Takeda, S. Uemura, M. Matsumoto, Y. Fujimura, J.-i. Jo, et al. Human Placental Ectonucleoside Triphosphate Diphosphohydrolase Gene Transfer via Gelatin-Coated Stents Prevents In-Stent Thrombosis Arterioscler. Thromb. Vasc. Biol., June 1, 2009; 29(6): 857 - 862. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Fishbein, I. Alferiev, M. Bakay, S. J. Stachelek, P. Sobolewski, M. Lai, H. Choi, I. -W. Chen, and R. J. Levy Local Delivery of Gene Vectors From Bare-Metal Stents by Use of a Biodegradable Synthetic Complex Inhibits In-Stent Restenosis in Rat Carotid Arteries Circulation, April 22, 2008; 117(16): 2096 - 2103. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Kundumani-Sridharan, D. Wang, M. Karpurapu, Z. Liu, C. Zhang, N. Dronadula, and G. N. Rao Suppression of Activation of Signal Transducer and Activator of Transcription-5B Signaling in the Vessel Wall Reduces Balloon Injury-Induced Neointima Formation Am. J. Pathol., October 1, 2007; 171(4): 1381 - 1394. [Abstract] [Full Text] [PDF] |
||||
![]() |
R R Anis and K R Karsch The future of drug eluting stents Heart, May 1, 2006; 92(5): 585 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Fishbein, I. S. Alferiev, O. Nyanguile, R. Gaster, J. M. Vohs, G. S. Wong, H. Felderman, I-W. Chen, H. Choi, R. L. Wilensky, et al. Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents PNAS, January 3, 2006; 103(1): 159 - 164. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |